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Abstract 
Background: Post-transfusion hepatitis (PTH) is majorly caused by hepatitis C virus (HCV). 
So, recipients of blood/blood products, post-transfusion hepatitis (PTH), renal dialysis patients 
and intravenous drug users all represent high-risk groups for infection. The aim of the present 
research was to determine the prevalence of HCV antibody in β-thalassemia major patients 
visiting different tertiary care hospital in Lahore, Pakistan.  
Methods: HCV seroprevalence and risk factors were studied in 200 β-thalassemia major 
patients (24 females, 176 males) with different age groups by second generation ELISA during 
January 2013 to May 2013. Confirmed β-thalassemia major patients from three different 
tertiary care hospitals were selected with special reference to age, age at the time of diagnosis, 
frequency of transfusion and present clinical status. 
Results: Among 200 patients, 82 (41%) were found reactive for HCV antibody with age range 
of 2 to 18 years with mean age of 8.5 years.  
Conclusion: This study showed that hemodialysis patients and β-thalassemia sufferers were at 
higher risk of having HCV infection; the prevalence being 41%. 
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Introduction 
β-thalassemia is among the most common 
genetic disorders in the world. It happens due 
to genetic defects in process of haemoglobin 
synthesis, β-thalassemia major is caused by 
defect in bête globin chain synthesis is the 
main clinical manifestation of this phenotype 
of disorder [1]. In order to avoid the chronic 
anemia in thalassaemic individuals, they may 
need to get 4‐6 blood units per month. They 
are also prone to blood borne infections. 
Multiple transfusions in patients of β-
thalassemia major who are treated by a 
regular transfusion regimen, are at a risk of 
developing transfusion transmitted infections 
(TTI) including hepatitis C. Children 
suffering from β-thalassemia major require 
repeated blood transfusions which may be 
associated with dangers like 
alloimmunization, iron overload, and 
contraction of infections such as HBV, HCV 
and HIV [2].  
In the absence of stem cell transplantation 
the disease is treated by lifelong red cell 
transfusion to keep the haemoglobin level 
between 9–11.5 g/dL. Regular blood 
transfusions are essential to maintain growth 
and development during childhood and also 
to sustain good quality of life during 
adulthood [3,4]. 
Patients with β-thalassemia major are at a 
high risk of developing hepatitis due to the 
transfusion of blood from donors infected 
with hepatitis B virus (HBV) [5]. The 
incidence of hepatitis B infections based on 
serological studies approaches 100% in β-
thalassemia major where HBV is endemic.' 
The incidence of this HCV antibody in blood 
transfusion recipients and donors, with PTH, 
and in other high risk groups, like patients 
with HIV, haemophilia, chronic hepatitis, 
homosexuals, needle stick victims is well 
established  [6].  
The management of β-thalassemia major 
essentially comprises of regular “safe blood 
transfusion” and a lifelong iron-chelation 
therapy. Unfortunately, our patients, even 
those managed at relatively better 
management centers, are prone to develop 
both types of complication, i.e., those 
transmitted through blood transfusion 
(particularly hepatitis C) as well as sequelae 
of transfusion siderosis. Hepatitis B has a 
declining trend, probably as a result of 
regular pre-transfusion screening for HBsAg, 
use of hepatitis B vaccination and improved 
public awareness about the disease. HIV 
infection, fortunately, is uncommon in our 
setup. Last decade has witnessed a 
tremendous increase in the sero-prevalence 
of hepatitis C amongst almost all the major 
cities of Pakistan. However, it has been 
observed that amongst blood donors 
belonging to different socioeconomic strata, 
this seroprevalence is variable; the figures are 
much lesser amongst young college students 
(0.7%) and non-remunerated donors (1.3%) 
as compared to factory workers (11.8%) [7].  
Furthermore, amongst the major 
transfusion transmitted infection (TTI) 
markers in our service, the overall HCV 
seroprevalence is high (4.1%) Life-long red 
blood cell (RBC) transfusion remains the 
main treatment for severe β-thalassemia [8]. 
The use of regular blood transfusion and of 
chelation therapy with deferoxamine has led 
to the transfusion of β-thalassemia major 
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from a fatal disease in early childhood to a 
chronic illness associated with prolonged 
survival [9,10]. 
Methods 
The whole bench work was conducted at the 
Ittefaq hospital (Trust) Lahore Pakistan. 
Data was obtained from 200 β-
thalassemia major patients aged one year or 
more receiving regular blood transfusions at 
a major transfusion center in Lahore 
Pakistan. Clinical data and laboratory results 
were subsequently checked. Anti HCV were 
found Reactive in 41% of cases of β-
thalassemia patients. Descriptive statistics 
were used to elaborate results. The samples 
of β-thalassemia patients were collected from 
different Hospital and clinical Lab of Lahore 
Pakistan Which includes Sundas Foundation, 
Fatmeed Foundation and Children Hospital, 
Lahore. Β-thalassemia major patients treated 
with ten or more transfusions were included 
in the study 
β-thalassemia subjects were selected by 
clinical history. Diagnosis of β-thalassemia 
was confirmed by standard haemoglobin 
electrophoresis clinical data of patients who 
fulfilled the criteria were collected and 
entered in the questionnaire, with special 
reference to age, age at the time of diagnosis, 
frequency of transfusion, present clinical 
status, any increase in transfusion 
requirements. Blood samples were obtained 
for detection of anti-HCV and red cell 
alloantibodies. The serum was separated 
using standard blood bank method and stored 
in labeled tubes at minus 20°C. Anti HCV 
screening was performed on instrument 
ARCHITECT (i 1000 SR) 
Chemiiluminescence (CMIA) Technology. 
Antibody Screenind. 
Results  
Of the total 200 cases studied 176 were males 
and 24 were females. The patient age ranged 
from 1 to 18 years were with mean age of 7.8 
years with ±SD 4.4. The age on first 
transfusion was 3 to 48 months with mean 
age of 9 months with ±SD 8.0 months. 
Among 200 patients 82 (41%) were Reactive 
for anti-HCV with age range of 2 to 18 years 
with mean age of 8.5 years. The mean age at 
1st transfusion was 8.7 months. Among them 
28 having blood group of O +ve, 25 B +ve, 
18 A +ve, 8 AB +ve and 3 were A -ve. 
Discussion 
The present study was conducted to find out 
the rate of alloimmunization and transfusion 
transmitted infection. Growth retardation is a 
common finding in thalassemics. The main 
reasons could be iron overload, associated 
endocrinopathies, hypoxia and chronic 
anemia. Slow growth rate with prolongation 
of growth period is seen in many cases and 
normal stature is rarely attained even in well 
managed patients. Some authors have 
described that, the rate of alloimmunization 
is increased after splenectomy. The reason 
put forward is that the spleen effectively 
filters many antigens that may probably 
cause production of antibodies. 
Early and regular blood transfusion in 
patients of β-β-thalassemia major decreases 
the complications of severe anemia and 
prolongs survival. It is particularly so in 
patients who are fortunate enough to receive 
an adequate, regular iron chelation therapy, 
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and are therefore protected from organ 
damage by iron overload. 
Fortunately, HBV infection can be, to a 
great extent, prevented by a pre-transfusion 
immunization, HCV infection has gained 
importance particularly as one of the major 
complications in multiply transfused patients 
during the last 10 years [11]. This is 
especially true for counties where HCV is 
more prevalent in general population and 
therefore also amongst blood donors. The 
prevalence rate of seropositivity increases 
with the number of transfusions [12]. This 
post transfusion hepatitis has significantly 
contributed to morbidity in β-thalassemia 
[13]. It should be remembered that HCV 
hepatitis is more threatening than HBV 
hepatitis due to a greater risk of chronic liver 
disease. 
In our study, a high prevalence of HCV 
seropositivity 41%, although patients were 
usually transfused at Ittefaq Hospital (trust) 
where pre-transfusion screening of the 
transfused is regularly performed. However, 
it was guessed during interview of the 
patients’ parents that in almost all instances, 
the patients did get transfused with blood 
from some other centers, where pre-
transfusion HCV antibody screening was not 
guaranteed. Furthermore, the parents of about 
60% of patients were not aware of the 
importance of HCV antibody screening of 
transfused blood. In many previous studies, 
the prevalence of HCV antibodies was 
observed to be reduced after the institution of 
a regular HCV screening before transfusion. 
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